Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MASP2 | O00187 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21565741 | 0.85 | ERCC1 (0.51) | ERCC1ERCC4PTGESMASP2KMT2A | |
| SCHEMBL12131750 | 0.84 | ERCC1 (0.70) | ERCC1ERCC4MAPTKMT2A | |
| SCHEMBL21565747 | 0.82 | TRPA1 (0.54) | ERCC1ERCC4PTGESMASP2KMT2A | |
| SCHEMBL24558042 | 0.79 | ERCC1 (0.64) | ERCC1ERCC4MAPTKMT2A | |
| SCHEMBL22060015 | 0.78 | ERCC1 (0.62) | ERCC1ERCC4MAPTKMT2A | |
| SCHEMBL18887748 | 0.78 | ERCC1 (0.67) | ERCC1ERCC4MAPTKMT2A | |
| SCHEMBL12134066 | 0.78 | ERCC1 (0.62) | ERCC1ERCC4MAPTKMT2A | |
| SCHEMBL12757443 | 0.78 | KMT2A (0.63) | ERCC1ERCC4KMT2A | |
| SCHEMBL18232464 | 0.76 | TPSAB1 (0.61) | ERCC1ERCC4KMT2A | |
| SCHEMBL13396910 | 0.76 | ERCC1 (0.60) | ERCC1ERCC4MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | ERCC1 4005/4885ERCC4 4784/4885PTGES 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.